Table 5

Sensitivity analyses, age standardised disability-adjusted life years (DALYs) per 100,000 population, and percentage difference (%Diff) as compared to the main analysis, Norway 2008
Cancer sites Sensitivity analysis 1a Sensitivity analysis 2b
DALYs %Diff DALYs %Diff
Lip oral cavity 46 2 46 2
Nasopharynx 3 0 3 0
Other pharynx 33 3 33 3
Oesophagus 80 1 80 1
Stomach 152 0 152 −1
Colorectum 643 1 643 0
Liver 48 0 48 0
Gallbladder 34 0 34 0
Pancreas 248 0 248 0
Larynx 20 5 - c - c
Lung 864 1 864 0
Melanoma of skin 180 1 180 0
Kaposi Sarcoma -d -d -d -d
Breast 587 4 587 3
Cervix uteri 102 1 102 1
Corpus uteri 84 1 84 0
Ovary 151 1 - e - e
Prostate 364 9 364 4
Testis 44 0 - e - e
Kidney 110 2 108 0
Bladder 105 1 105 1
Brain, nervous system 281 3 - c - c
Thyroid 11 0 - e - e
Hematological cancers - f - f - f - f

a Sensitivity analysis 1: Two-stage disease model as compared to three stage disease model.

b Sensitivity analysis 2: Proportion of advanced cases used as proxy of patients who did not receive (curatively intentioned) treatment as compared to use of available treatment data.

c Staging data were not available.

d Treatment and staging data were not available.

e Proportion cured was larger than proportion of advanced cases, analysis was not done.

f Sensitivity analyses 1 and 2 were not done for haematological cancers.

Soerjomataram et al.

Soerjomataram et al. BMC Medical Research Methodology 2012 12:125   doi:10.1186/1471-2288-12-125

Open Data